Weekly update Companies AI-cruiter Recruiting

Avidity Biosciences

Founded: 2013

Location: La Jolla, CA

Employee range: 50 - 200

Clinical stage: Clin1/Clin2

Therapy area: Myotonic dystrophy type 1

Drug types: GEN, MUS, RAR, CVV

Lead product: AOC 1001

Product link: https://www.aviditybiosciences.com/pipeline/pipeline-overview/

Funding: $207M stock Dec 2022; $298M IPO Jun 2020; $100M C Nov 2019; $16M B Jan 2017

aviditybiosciences.com

linkedin.com

job board

Short description:

Antibody-Oligonucleotide Conjugates

Drug notes:

AOC 1044 Clin1/Clin2 DMD (FT); AOC 1020 Clin1/Clin2 facioscapulohumeral muscular dystrophy; 3+ undisclosed programs RD DMD, skeletal muscle conditions, rare cardiac conditions

Long description:

Avidity Biosciences is developing a new class of RNA therapies to treat rare genetic diseases. Avidity has developed an innovative pipeline built upon their Antibody Oligonucleotide Conjugate (AOCTM) platform. AOCs comprise three components: monoclonal antibodies (mAbs), a linker and siRNA. AOCs therefore combine the specificity of mAbs and the precision of oligonucleotides which enable tissue-specific and gene-specific targeting, respectively. Avidity has primarily focused on skeletal muscle diseases with AOC 1001 now in clinical trials and is looking to expand into different cells and tissues. This can be achieved through the flexibility of the AOC platform.